SCHEMBL10003403

SCHEMBL10003403

CCc1cc2c(nc1-c1cccs1)c(OC(C)C)c(C(=O)O)n2C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERCC1 P07992 1/20 0.35
▸ FEN1 P39748 1/20 0.35
▸ ERCC4 Q92889 1/20 0.35
▸ KDM4E B2RXH2 4/20 0.35
▸ MAPT P10636 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ SRPK1 Q96SB4 1/20 0.34
▸ RPS6KB2 Q9UBS0 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ SMPD3 Q9NY59 1/20 0.34
▸ ADORA2A P29274 2/20 0.34
▸ ADORA1 P30542 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ ADCY1 Q08828 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003647 0.90 MAPT (0.42) KDM4EMAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL10003857 0.85 MCL1 (0.36) KDM4EMAPTTP53ALDH1A1RAB9A
SCHEMBL10004423 0.82 RAB9A (0.42) KDM4EMAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL10003803 0.81 MAPT (0.35) KDM4EMAPTALDH1A1RAB9AMEN1
SCHEMBL10003106 0.80 GRIA2 (0.37) KDM4EMAPTTP53ALDH1A1ADORA2A
SCHEMBL10003551 0.80 GRIA2 (0.37) KDM4EALDH1A1HPGD
SCHEMBL10003897 0.80 SMO (0.42) TP53ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL10003507 0.80 GRIA2 (0.39) KDM4EMAPTTHRBALDH1A1RAB9A
SCHEMBL10003241 0.80 PPARD (0.38) —
SCHEMBL10003186 0.77 BRPF1 (0.44) KDM4EMAPTTP53ALDH1A1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ERCC1 3666/4885FEN1 3991/4885ERCC4 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback